The FDA on April 23, 2025, approved Penpulimab-kcqx with Cisplatin or Carboplatin and Gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing NasoPharyngeal Carcinoma (NPC). Penpulimab-kcqx is a product of Akeso Biopharma Co., Ltd.
Bottom Ad
Advertisement
Subscribe
